"JPM26: Eli Lilly reportedly eyes €15bn takeover of Abivax" was originally created and published by Pharmaceutical Technology ...

France's Finance ​Ministry said on Monday it had received no formal request for investment approval ‌regarding French biotech ...

Eli Lilly’s presence in France has spanned more than six decades, but rumors of an acquisition suggest the pharmaceutical ...

France's Finance Ministry refutes reports of Eli Lilly's intent to acquire French biotech Abivax for €15 billion. Abivax shares spiked following the rumors but receded after the Ministry's denial.

Stock in the French company has been rising steadily since late July, and climbed as much as 30% in early trading Monday.

Abivax (ABVX) stays a Buy as obefazimod UC data fuels multi‑billion potential; 2026 Phase 3/NDA catalysts loom and M&A ...

Eli Lilly stock prepares €15B Abivax acquisition as tirzepatide revenue hits $24.8B. Orforglipron oral weight loss drug ...

French newspaper La Lettre said the Paris-based biotech – which is listed on the Nasdaq – has been on Lilly's radar after ...

Shares in Abivax soared 23%, exceeding 121 euros, on Monday after a media report said U.S. pharma giant Eli Lilly was ‍still interested in buying the French biotech company. French media La Lettre ...

Shares in Abivax jumped sharply on Monday after a report said U.S. drugmaker Eli Lilly remains interested in acquiring the French biotech.

According to a story in the French-language newspaper La Tribune on December 24, 2025, there have been rumors that Eli Lilly ...

Investing.com -- Eli Lilly is preparing to offer €15 billion to acquire French biotech company Abivax, according to a Monday report from La Lettre. The U.S. pharmaceutical giant has not yet submitted ...